Ivermectin Orion

Ivermectin, the active ingredient in Ivermectin Orion, is an anthelmintic presented as an oral tablet for oral use. It is employed to treat parasitic infections such as onchocerciasis, strongyloidiasis, scabies and lymphatic filariasis in affected patients. It works by binding to parasite‑specific glutamate‑gated chloride channels, increasing membrane permeability to chloride ions, leading to paralysis and death of the parasite.

GNH USA supplies Ivermectin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU manufacturing standards and providing reliable logistics for global health programs.

Ivermectin Orion is used to treat parasitic diseases by targeting helminths and ectoparasites.

- Onchocerciasis: reduces microfilarial load and helps prevent skin and eye disease. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions. - Lymphatic filariasis: decreases microfilariae in the bloodstream, aiding control of transmission.

Adverse reactions may occur with oral ivermectin therapy.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring shortly after dosing. - Abdominal pain: cramping or discomfort in the stomach region. - Headache: mild to moderate tension‑type headache. - Pruritus: mild itching at the site of parasite die‑off.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic effects: seizures, altered mental status, or ataxia. - Hypotension: marked drop in blood pressure. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before prescribing Ivermectin Orion, clinicians should consider several safety aspects.

- Assess contraindications: avoid in patients with known hypersensitivity to ivermectin or its excipients. - Evaluate hepatic function: use caution in patients with severe liver disease. - Monitor for neurologic signs: especially in patients with high parasite burden or co‑infection. - Review concomitant medications: consider potential interactions that may increase ivermectin exposure. - Pregnancy and lactation: weigh benefits against potential risks; limited data are available. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct light.

Ivermectin Orion may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may raise ivermectin plasma concentrations and increase toxicity. - Neurotoxic agents (e.g., albendazole, levetiracetam): additive central nervous system depression. - Anticoagulants (e.g., warfarin): potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Antacids: may reduce oral absorption of ivermectin. - Macrolide antibiotics (e.g., erythromycin): modest increase in ivermectin levels. - Benzodiazepines: monitor for enhanced sedation. - P-glycoprotein substrates: possible altered distribution. - Herbal supplements (e.g., St. John’s wort): may affect metabolism.